Women's Health Market Analysis By Application (Postmenopausal Osteoporosis, Infertility, Endometriosis, Contraceptives, Menopause, Polycystic Ovary Syndrome), By Region, And Segment Forecasts, 2014 - 2025

  • ID: 4429707
  • Report
  • 110 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Agile Therapeutics
  • Allergan
  • Amgen, Inc.
  • AstraZeneca
  • Bayer AG
  • Ferring B.V.
  • MORE
The global women’s health market is expected to reach USD 51.3 billion by 2025, according to a new report. Increasing female geriatric population, introduction of various drugs related to women’s health, and favorable government policies are some of the factors expected to drive growth during the forecast period.

Women are more prone to certain diseases, such as osteoporosis, osteoarthritis, anemia, menstruation-related disorders, depression, and obesity. Hence, increase in incidence of these conditions is likely to boost the market in the coming years. According to International Osteoporosis Foundation, global prevalence of osteoporosis among women was over 200.0 million in 1990, and this is anticipated to reach 680.0 million in 2050.

Government and various private organizations are working toward improving women’s health across the world, and this is likely to drive growth in the coming years. Reimbursement coverage provided to women is also a key factor driving the market in developed countries. For instance, various coverage plans in the U.S. provide preventive services for women without charging any copayment. These include screening for anemia, hepatitis B, & breast cancer on a routine basis, folic acid supplements for women who are likely to be pregnant, and contraceptive methods, among others.

Further Key Findings From the Report Suggest:
  • Presence of a large female geriatric population, which is susceptible to chronic diseases, is expected to boost growth
  • In 2016, postmenopausal osteoporosis accounted for the largest share of the market due to high incidence of osteoporosis in women after menopause, presence of several major players, and cost-effectiveness of this treatment
  • Contraceptive segment is likely to witness fastest growth during the forecast period due to increase in awareness and usage, government initiatives, technological developments, and favorable regulatory scenario. For instance, in June 2017, Agile Therapeutics, Inc. resubmitted an NDA for Twirla, an investigational low-dose combined hormonal contraceptive patch
  • Geographically, North America held the largest share of more than 30% in 2016 due to presence of major market players, high awareness about regular health check-ups for women, coverage for screening, and increased healthcare expenditure
  • Asia Pacific is expected to exhibit fastest growth during the forecast period due to increasing investments by players in the region, rising awareness about women’s health, and initiatives by various governments and private organizations to improve awareness and access to women’s health products
  • Some of the key players operating in the women’s health market are Allergan; Bayer AG; Merck & Co., Inc.; Pfizer, Inc.; Teva Pharmaceutical Industries Ltd.; Agile Therapeutics; Amgen, Inc.; AstraZeneca; Bristol-Myers Squibb Company; and Ferring B.V.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Agile Therapeutics
  • Allergan
  • Amgen, Inc.
  • AstraZeneca
  • Bayer AG
  • Ferring B.V.
  • MORE
Chapter 1. Research Methodology
1.1. Information Procurement
1.2. Data Analysis

Chapter 2. Executive Summary
2.1. Market Snapshot

Chapter 3. Women’s Health Market Variables, Trends & Scope
3.1. Market Segmentation & Scope
3.1.1. Market driver analysis
3.1.1.1. Rising incidence of target disorders
3.1.1.2. Child or early marriages
3.1.1.3. Initiatives by governments and various organizations
3.1.2. Market restraint analysis
3.1.2.1. Patent expiry of major drugs
3.2. Penetration & Growth Prospect Mapping
3.3. Women’s Health - SWOT Analysis, by Factor (Political & Legal, Economic, and Technological)
3.4. Industry Analysis - Porter’s
3.5. Women’s Health Market: Market Position Analysis (Based on Products, Regional Presence, and Recent Updates

Chapter 4. Women’s Health Market: Drug Estimates & Trend Analysis
4.1. Women’s Health: Drug Analysis
4.1.1. Evista
4.1.1.1. Evista market, 2014 - 2025 (USD Million)
4.1.2. Prolia
4.1.2.1. Prolia market, 2014 - 2025 (USD Million)
4.1.3. Mirena
4.1.3.1. Mirena market, 2014 - 2025 (USD Million)
4.1.4. Zometa
4.1.4.1. Zometa market, 2014 - 2025 (USD Million)
4.1.5. Reclast/Aclasta
4.1.5.1. Reclast/Aclasta market, 2014 - 2025 (USD Million)
4.1.6. Minastrin 24FE
4.1.6.1. Minastrin 24FE market, 2014 - 2025 (USD Million)
4.1.7. NuvaRing
4.1.7.1. NuvaRing market, 2014 - 2025 (USD Million)
4.1.8. Forteo
4.1.8.1. Forteo market, 2014 - 2025 (USD Million)
4.1.9. Premarin
4.1.9.1. Premarin market, 2014 - 2025 (USD Million)
4.1.10. Actonel
4.1.10.1. Actonel market, 2014 - 2025 (USD Million)
4.1.11. Ortho-Tri-Cy LO 28
4.1.11.1. Ortho-Tri-Cy LO 28 market, 2014 - 2025 (USD Million)

Chapter 5. Women’s Health Market: Application Estimates & Trend Analysis
5.1. Women’s Health: Application Analysis
5.1.1. Postmenopausal osteoporosis
5.1.1.1. Postmenopausal osteoporosis market, 2014 - 2025 (USD Million)
5.1.2. Hormonal infertility
5.1.2.1. Hormonal infertility market, 2014 - 2025 (USD Million)
5.1.3. Endometriosis
5.1.3.1. Endometriosis market, 2014 - 2025 (USD Million)
5.1.4. Contraceptives
5.1.4.1. Contraceptives market, 2014 - 2025 (USD Million)
5.1.5. Menopause
5.1.5.1. Menopause market, 2014 - 2025 (USD Million)
5.1.6. Polycystic Ovary Syndrome (PCOS)
5.1.6.1. Polycystic ovary syndrome market, 2014 - 2025 (USD Million)

Chapter 6. Women’s Health Market: Regional Estimates & Trend Analysis
6.1. Women’s Health Market Share by Region, 2016 & 2025
6.2. North America
6.2.1. US
6.2.1.1. U.S. women’s health market, 2014 - 2025 (USD Million)
6.2.2. Canada
6.2.2.1. Canada women’s health market, 2014 - 2025 (USD Million)
6.3. Europe
6.3.1. Europe women’s health market, 2014 - 2025 (USD Million)
6.3.2. UK
6.3.2.1. UK women’s health market, 2014 - 2025 (USD Million)
6.3.3. Germany
6.3.3.1. Germany women’s health market, 2014 - 2025 (USD Million)
6.4. Asia Pacific
6.4.1. Asia Pacific women’s health market, 2014 - 2025 (USD Million)
6.4.2. Japan
6.4.2.1. Japan women’s health market, 2014 - 2025 (USD Million)
6.4.3. China
6.4.3.1. China women’s health market, 2014 - 2025 (USD Million)
6.5. Latin America
6.5.1. Latin America women’s health market, 2014 - 2025 (USD Million)
6.5.2. Brazil
6.5.2.1. Brazil women’s health market, 2014 - 2025 (USD Million)
6.5.3. Mexico
6.5.3.1. Mexico women’s health market, 2014 - 2025 (USD Million)
6.6. Middle East and Africa
6.6.1. Middle East & Africa women’s health market, 2014 - 2025 (USD Million)
6.6.2. South Africa
6.6.2.1. South Africa women’s health market, 2014 - 2025 (USD Million)

Chapter 7. Competitive Landscape
7.1. Strategy Framework
7.2. Company Profiles
7.2.1. Allergan
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. Bayer AG
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Merck & Co., Inc.
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Pfizer, Inc.
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Teva Pharmaceutical Industries Ltd.
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Agile Therapeutics
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Amgen, Inc.
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Apothecus Pharmaceutical Corporation
7.2.8.1. Company overview
7.2.8.2. Product benchmarking
7.2.9. AstraZeneca
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product pipeline
7.2.9.4. Product benchmarking
7.2.9.5. Strategic initiatives
7.2.10. Blairex Laboratories, Inc.
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.11. Bristol-Myers Squibb Company
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. Ferring B.V.
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives

List of Tables

Table 1 North America women’s health market, by country, 2014 - 2025 (USD Million)
Table 2 North America women’s health market, by application, 2014 - 2025 (USD Million)
Table 3 U.S. women’s health market, by application, 2014 - 2025 (USD Million)
Table 4 Canada women’s health market, by application, 2014 - 2025 (USD Million)
Table 5 Europe women’s health market, by country, 2014 - 2025 (USD Million)
Table 6 Europe women’s health market, by application, 2014 - 2025 (USD Million)
Table 7 UK women’s health market, by application, 2014 - 2025 (USD Million)
Table 8 Germany women’s health market, by application, 2014 - 2025 (USD Million)
Table 9 Asia Pacific (APAC) women’s health market, by country, 2014 - 2025 (USD Million)
Table 10 Asia Pacific women’s health market, by application, 2014 - 2025 (USD Million)
Table 11 Japan women’s health market, by application, 2014 - 2025 (USD Million)
Table 12 China women’s health market, by application, 2014 - 2025 (USD Million)
Table 13 Latin America (LATAM) women’s health market, by country, 2014 - 2025 (USD Million)
Table 14 Latin America women’s health market, by application, 2014 - 2025 (USD Million)
Table 15 Brazil women’s health market, by application, 2014 - 2025 (USD Million)
Table 16 Mexico women’s health market, by application, 2014 - 2025 (USD Million)
Table 17 Middle East & Africa (MEA) women’s health market, by country, 2014 - 2025 (USD Million)
Table 18 Middle East & Africa (MEA) women’s health market, by application, 2014 - 2025 (USD Million)
Table 19 South Africa women’s health market, by application, 2014 - 2025 (USD Million)

List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain based sizing & forecasting
FIG. 6 QFD Modelling For Market Share Assessment
FIG. 7 Market summary 2016, (USD Million)
FIG. 8 Market trends & outlook
FIG. 9 Market segmentation & scope
FIG. 10 Market driver relevance analysis (Current & future impact)
FIG. 11 Market restraint relevance analysis (Current & future impact)
FIG. 12 Penetration & growth prospect mapping
FIG. 13 SWOT analysis, by factor (political & legal, economic, and technological)
FIG. 14 Porter’s five forces analysis
FIG. 15 Women’s health competitive landscape: Market position analysis (based on products, regional presence (2016)
FIG. 16 Evista market, 2014 - 2025 (USD Million)
FIG. 17 Prolia market, 2014- 2025 (USD Million)
FIG. 18 Mirena market, 2014 - 2025 (USD Million)
FIG. 19 Zometa market, 2014 - 2025 (USD Million)
FIG. 20 Reclast/Aclasta market, 2014 - 2025 (USD Million)
FIG. 21 Minastrin 24FE market, 2014 - 2025 (USD Million)
FIG. 22 NuvaRing market, 2014 - 2025 (USD Million)
FIG. 23 Forteo market, 2014 - 2025 (USD Million)
FIG. 24 Premarin market, 2014 - 2025 (USD Million)
FIG. 25 Actonel market, 2014 - 2025 (USD Million)
FIG. 26 Ortho-Tri-Cy LO 28 market, 2014 - 2025 (USD Million)
FIG. 27 Women’s health market: Application outlook key takeaways
FIG. 28 Women’s health: Application movement analysis
FIG. 29 Postmenopausal osteoporosis market, 2014 - 2025 (USD Million)
FIG. 30 Hormonal infertility market, 2014- 2025 (USD Million)
FIG. 31 Endometriosis market, 2014 - 2025 (USD Million)
FIG. 32 Contraceptives market, 2014 - 2025 (USD Million)
FIG. 33 Menopause market, 2014 - 2025 (USD Million)
FIG. 34 Polycystic ovary syndrome market, 2014 - 2025 (USD Million)
FIG. 35 Regional market place: key takeaways
FIG. 36 Regional outlook, 2016 & 2025
FIG. 37 North America women’s health market, 2014 - 2025 (USD Million)
FIG. 38 U.S. women’s health market, 2014 - 2025 (USD Million)
FIG. 39 Canada women’s health market, 2014 - 2025 (USD Million)
FIG. 40 Europe women’s health market, 2014 - 2025 (USD Million)
FIG. 41 UK women’s health market, 2014 - 2025 (USD Million)
FIG. 42 Germany women’s health market, 2014 - 2025 (USD Million)
FIG. 43 Asia Pacific women’s health Market, 2014 - 2025 (USD Million)
FIG. 44 Japan women’s health market, 2014 - 2025 (USD Million)
FIG. 45 China women’s health market, 2014 - 2025 (USD Million)
FIG. 46 Latin America women’s health market, 2014 - 2025 (USD Million)
FIG. 47 Brazil women’s health market, 2014 - 2025 (USD Million)
FIG. 48 Mexico women’s health market, 2014 - 2025 (USD Million)
FIG. 49 Middle East & Africa women’s health market, 2014 - 2025 (USD Million)
FIG. 50 South Africa women’s health Market, 2014 - 2025 (USD Million)
FIG. 51 Strategy framework
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Allergan
  • Bayer AG
  • Merck & Co., Inc.
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Agile Therapeutics
  • Amgen, Inc.
  • Apothecus Pharmaceutical Corporation
  • AstraZeneca
  • Blairex Laboratories, Inc.
  • Bristol-Myers Squibb Company
  • Ferring B.V.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll